Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

Rhea-AI Summary

Precigen (Nasdaq: PGEN) announced a virtual fireside chat with H.C. Wainwright on March 31, 2026 from 11:00 AM to 12:00 PM ET. Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer, will participate.

Participants can view event details and access the webcast via Precigen's Events & Presentations page at investors.precigen.com/events-presentations.

Key Figures

Fireside chat time: 11:00 AM – 12:00 PM ET

1 metrics

Fireside chat time 11:00 AM – 12:00 PM ET Virtual H.C. Wainwright fireside chat on March 31, 2026

Market Reality Check

Price: $3.67 Vol: Volume 7,039,854 vs 20-da...

normal vol

$3.67 Last Close

Volume Volume 7,039,854 vs 20-day average 4,923,531 (relative volume 1.43x) ahead of the event-focused news. normal

Technical Shares trade modestly above the 200-day MA ($3.67 vs $3.45) while sitting 32.85% below the 52-week high.

Peers on Argus

PGEN fell 5.66% while key biotech peers like NTLA (-5.68%) and RCUS (-4.83%) als...

PGEN fell 5.66% while key biotech peers like NTLA (-5.68%) and RCUS (-4.83%) also traded lower. However, no peers appeared in the momentum scanner and sector_move is flagged false, suggesting today’s action is viewed as more stock-specific than a coordinated sector rotation.

Historical Context

5 past events · Latest: Mar 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 25	Earnings and updates	Positive	+25.5%	Full-year 2025 results and PAPZIMEOS commercialization and regulatory milestones.
Mar 11	Earnings date notice	Neutral	-4.1%	Announcement of date and call details for upcoming full-year 2025 results.
Jan 20	Clinical consensus news	Positive	-0.5%	Independent consensus recommending PAPZIMEOS as new first-line RRP standard of care.
Jan 12	Commercial momentum	Positive	-9.9%	Update on rapid PAPZIMEOS commercialization, coverage and operational readiness at JPM.
Jan 05	Conference participation	Positive	+8.8%	Notice of CEO presentation and fireside chat at J.P. Morgan Healthcare Conference.

Pattern Detected

Recent history shows mixed reactions: strong gains on major earnings and conference updates, but occasional selloffs or flat trading after otherwise positive commercialization news.

Recent Company History

Over the last six months, PGEN transitioned to a commercial-stage story centered on PAPZIMEOS. Earnings on Mar 25, 2026 with commercial and regulatory milestones saw a 25.48% gain, while a J.P. Morgan conference presentation on Jan 5, 2026 rose 8.85%. Other positive commercialization updates on Jan 12 and expert consensus news on Jan 20 coincided with declines, highlighting that good fundamental news has not always produced supportive price action. Today’s routine fireside chat notice fits the ongoing investor-relations cadence.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-08-19

An effective Form S-3 shelf dated Aug 19, 2025 registers secondary sales of common and preferred stock by selling stockholders, with the company receiving no proceeds. The registration allows various sale methods (including at-the-market and block trades) and highlights concentrated ownership controlled by R.J. Kirk and affiliates.

Market Pulse Summary

This announcement adds another investor-relations event to PGEN’s recent cadence, following earnings...

Analysis

This announcement adds another investor-relations event to PGEN’s recent cadence, following earnings on Mar 25, 2026 and multiple conference appearances. The company remains a commercial-stage biotech focused on PAPZIMEOS and a broader immunotherapy pipeline. Investors may watch upcoming presentations for updated commercialization metrics and pipeline details, while also tracking any use of the existing Form S-3 secondary registration by selling stockholders.

Key Terms

immuno-oncology

1 terms

immuno-oncology medical

"its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases."

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

AI-generated analysis. Not financial advice.

GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO, and Phil Tennant, Chief Commercial Officer, of Precigen, will participate in a virtual fireside chat with H.C. Wainwright on March 31, 2026 from 11:00 AM – 12:00 PM ET.

Participants may view details for this event on Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

Precigen: Advancing Medicine with Precision^®
Precigen (Nasdaq: PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company's future financial and operational results including the Company's ability to reach cash flow break-even, and the Company's ability to commence clinical studies or complete ongoing clinical studies for the Company's clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
investors@precigen.com

Media Contact:
Donelle M. Gregory
press@precigen.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/precigen-to-participate-in-a-fireside-chat-with-hc-wainwright-on-march-31-302728209.html

SOURCE Precigen, Inc.

FAQ

When is Precigen (PGEN) hosting the H.C. Wainwright fireside chat?

The fireside chat is scheduled for March 31, 2026, 11:00 AM–12:00 PM ET. According to Precigen, Helen Sabzevari and Phil Tennant will participate and the virtual event is viewable via the company's Events & Presentations web page for investors.

Who will represent Precigen (PGEN) in the March 31, 2026 fireside chat?

Precigen will be represented by Helen Sabzevari, PhD (President & CEO) and Phil Tennant (Chief Commercial Officer). According to Precigen, both executives will participate in the virtual discussion hosted by H.C. Wainwright.

How can investors access the Precigen (PGEN) March 31, 2026 virtual event?

Investors can view event details and the webcast on Precigen's Events & Presentations page at investors.precigen.com/events-presentations. According to Precigen, the site provides registration and access information for the March 31, 2026 virtual fireside chat.

What will the Precigen (PGEN) fireside chat with H.C. Wainwright cover on March 31, 2026?

The event will feature executive discussion about Precigen's business and pipeline developments led by company leadership. According to Precigen, the virtual fireside chat offers investor-focused commentary from the CEO and chief commercial officer.

Is there a replay available for the Precigen (PGEN) H.C. Wainwright fireside chat if I miss the live March 31, 2026 session?

Precigen typically posts event replays on its investor site after the live session. According to Precigen, attendees should check the Events & Presentations page for on-demand access or replay information following the March 31, 2026 fireside chat.